Effect of Xuezhikang Capsule on serum tumor necrosis factor-alpha and interleukin-6 in patients with nonalcoholic fatty liver disease and hyperlipidemia.
OBJECTIVE
To evaluate the effect of Xuezhikang Capsule on the serum levels of inflammatory factors such as tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6) in patients with nonalcoholic fatty liver disease (NAFLD) and hyperlipidemia, and to explore whether it has anti-inflammatory effect.


METHODS
A total of 84 patients were randomly assigned to two groups with stratified block randomization, the treatment group (42 cases) and the control group (42 cases). They were treated with Xuezhikang Capsule and polyene phosphatidylcholine capsule for twenty-four weeks, respectively. The changes in serum TNF-alpha and IL-6 were measured by enzyme linked immunosorbent assay before treatment and at the 12th and 24th week.


RESULTS
Compared with those before treatment, the serum levels of TNF-alpha and IL-6 significantly decreased in both groups after treatment (P<0.01). There was no significant change between the two groups for the treatments at different time points (P>0.05) and between the two groups for treatments at the same time points (P>0.05).


CONCLUSIONS
Xuezhikang Capsule can inhibit the serum inflammatory factor in patients with NAFLD and hyperlipidemia.
Fan
Xiao-fen
XF
Department of Traditional Chinese Medicine, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou (310003), China.
Deng
Yin-quan
YQ
Ye
Lei
L
Li
You-di
YD
Chen
Jiu
J
Lu
Wen-wen
WW
Li
Jian-ping
JP
D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage / Q000494:pharmacology; D002214:Capsules; D004365:Drugs, Chinese Herbal / Q000008:administration & dosage / Q000494:pharmacology*; D005234:Fatty Liver / Q000097:blood* / Q000150:complications / Q000188:drug therapy; D005260:Female; D006801:Humans; D006949:Hyperlipidemias / Q000097:blood* / Q000150:complications / Q000188:drug therapy; D000960:Hypolipidemic Agents / Q000008:administration & dosage / Q000494:pharmacology; D015850:Interleukin-6 / Q000097:blood*; D008055:Lipids / Q000097:blood; D008099:Liver / Q000187:drug effects / Q000503:physiopathology; D008111:Liver Function Tests; D008297:Male; D008875:Middle Aged; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000097:blood*
D000894:Anti-Inflammatory Agents, Non-Steroidal; D002214:Capsules; D004365:Drugs, Chinese Herbal; D000960:Hypolipidemic Agents; D015850:Interleukin-6; D008055:Lipids; D014409:Tumor Necrosis Factor-alpha; C496822:xuezhikang
J Biol Chem. 2003 Nov 14;278(46):45777-84
12952969
Zhonghua Gan Zang Bing Za Zhi. 2006 Aug;14(8):613-5
16938178
J Gastroenterol Hepatol. 2003 May;18(5):588-94
12702052
Am J Clin Nutr. 1999 Feb;69(2):231-6
9989685
Atherosclerosis. 2003 Jun;168(2):375-80
12801622
Nature. 2002 Nov 21;420(6913):333-6
12447443
Gene. 2003 Dec 4;321:1-15
14636987
J Biol Chem. 2003 Apr 18;278(16):13740-6
12560330